JP2009532338A - Ｐｓｍａのペプチド模倣体阻害剤、それらを含む化合物、およびそれらの使用方法 - Google Patents

Ｐｓｍａのペプチド模倣体阻害剤、それらを含む化合物、およびそれらの使用方法 Download PDF

Info

Publication number
JP2009532338A
JP2009532338A JP2009500598A JP2009500598A JP2009532338A JP 2009532338 A JP2009532338 A JP 2009532338A JP 2009500598 A JP2009500598 A JP 2009500598A JP 2009500598 A JP2009500598 A JP 2009500598A JP 2009532338 A JP2009532338 A JP 2009532338A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
hydroxy
amino
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532338A5 (enExample
Inventor
クリフ バークマン，
Original Assignee
キャンサー ターゲテッド テクノロジー エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャンサー ターゲテッド テクノロジー エルエルシー filed Critical キャンサー ターゲテッド テクノロジー エルエルシー
Publication of JP2009532338A publication Critical patent/JP2009532338A/ja
Publication of JP2009532338A5 publication Critical patent/JP2009532338A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2416—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
JP2009500598A 2006-03-14 2007-03-14 Ｐｓｍａのペプチド模倣体阻害剤、それらを含む化合物、およびそれらの使用方法 Pending JP2009532338A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78221106P 2006-03-14 2006-03-14
PCT/US2007/064002 WO2007106869A1 (en) 2006-03-14 2007-03-14 Peptidomimetic inhibitors of psma,compounds comprising them, and methods of use

Publications (2)

Publication Number Publication Date
JP2009532338A true JP2009532338A (ja) 2009-09-10
JP2009532338A5 JP2009532338A5 (enExample) 2011-04-28

Family

ID=38229662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009500598A Pending JP2009532338A (ja) 2006-03-14 2007-03-14 Ｐｓｍａのペプチド模倣体阻害剤、それらを含む化合物、およびそれらの使用方法

Country Status (9)

Country Link
US (3) US7696185B2 (enExample)
EP (1) EP1999136B1 (enExample)
JP (1) JP2009532338A (enExample)
CN (1) CN101443340B (enExample)
AU (1) AU2007226542B2 (enExample)
CA (1) CA2645809C (enExample)
ES (1) ES2397973T3 (enExample)
PL (1) PL1999136T3 (enExample)
WO (1) WO2007106869A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011195461A (ja) * 2010-03-17 2011-10-06 Nikko Chemical Co Ltd ポリオキシアルキレンステロールエーテル誘導体及び／又はポリオキシアルキレンスタノールエーテル誘導体、及びそれを含有する外用剤組成物
JP2016531297A (ja) * 2013-08-27 2016-10-06 ギルピ ゲーエムベーハー 疾患関連標的構造の検出のための診断デバイス
JP2018535925A (ja) * 2015-09-09 2018-12-06 オン ターゲット ラボラトリーズ エルエルシー Ｐｓｍａ標的化ｎｉｒ色素およびその使用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926573C (en) * 2007-06-26 2018-08-28 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2010045598A2 (en) * 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2010149666A1 (en) * 2009-06-22 2010-12-29 Medexis S.A. Methods for treating neoplasia
EP2338892A1 (en) 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2011106639A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9328129B2 (en) 2010-11-12 2016-05-03 Washington State University Peptidomimetic inhibitors of PSMA
CN103930432B (zh) * 2011-06-15 2017-06-23 癌靶技术有限责任公司 螯合的psma抑制剂
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
AU2013344778C1 (en) 2012-11-15 2024-06-27 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
EP2970345B1 (en) 2013-03-15 2019-06-19 Cancer Targeted Technology LLC 18f-labeled psma-targeted pet imaging agents
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN105849568B (zh) 2013-11-14 2018-05-04 恩多塞特公司 用于正电子发射断层术的化合物
US10383912B2 (en) * 2014-08-18 2019-08-20 Washington State University Tunable pH-sensitive linker for controlled drug release
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2018031809A1 (en) 2016-08-10 2018-02-15 Cancer Targeted Technology Llc Chelated psma inhibitors
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
IL287989B2 (en) * 2019-05-13 2025-07-01 Bracco Imaging Spa Modified cyanine dyes and their conjugates
JP7604397B2 (ja) 2019-05-20 2024-12-23 エンドサイト・インコーポレイテッド Ｐｓｍａコンジュゲートの調製方法
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
CN113117099B (zh) * 2019-12-31 2022-07-15 广东精观生物医药科技有限公司 一种靶向psma的荧光分子探针及其制备方法和应用
CN111675747B (zh) * 2020-07-30 2021-04-27 中国医学科学院医药生物技术研究所 抗肿瘤药物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507857A (ja) * 2001-02-07 2005-03-24 ベズ イズレイル ディーコネス メディカル センター 改変ｐｓｍａリガンド及びそれに関する利用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US782211A (en) 1904-05-23 1905-02-07 George W Sturgis Vending-wagon.
TR199802638T2 (xx) * 1996-06-17 1999-03-22 Guilford Pharmaceuticals, Inc. Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
WO2002046448A2 (en) * 2000-11-20 2002-06-13 Eastern Virginia Medical School Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
KR20040077889A (ko) * 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507857A (ja) * 2001-02-07 2005-03-24 ベズ イズレイル ディーコネス メディカル センター 改変ｐｓｍａリガンド及びそれに関する利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012044151; ＢＯＯＫ　ＯＦ　ＡＢＳＴＲＡＣＴＳ，　２２９ＴＨ　ＡＣＳ　ＮＡＴＩＯＮＡＬ　ＭＥＥＴＩＮＧ ２２９, 2005, ＭＥＤＩ４８０ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011195461A (ja) * 2010-03-17 2011-10-06 Nikko Chemical Co Ltd ポリオキシアルキレンステロールエーテル誘導体及び／又はポリオキシアルキレンスタノールエーテル誘導体、及びそれを含有する外用剤組成物
JP2016531297A (ja) * 2013-08-27 2016-10-06 ギルピ ゲーエムベーハー 疾患関連標的構造の検出のための診断デバイス
JP2018535925A (ja) * 2015-09-09 2018-12-06 オン ターゲット ラボラトリーズ エルエルシー Ｐｓｍａ標的化ｎｉｒ色素およびその使用

Also Published As

Publication number Publication date
EP1999136B1 (en) 2012-10-24
AU2007226542A1 (en) 2007-09-20
CN101443340A (zh) 2009-05-27
PL1999136T3 (pl) 2013-03-29
US8293725B2 (en) 2012-10-23
US20070219165A1 (en) 2007-09-20
USRE42275E1 (en) 2011-04-05
CA2645809A1 (en) 2007-09-20
WO2007106869A1 (en) 2007-09-20
EP1999136A1 (en) 2008-12-10
CN101443340B (zh) 2013-12-04
US20100183517A1 (en) 2010-07-22
AU2007226542B2 (en) 2013-08-22
ES2397973T3 (es) 2013-03-12
CA2645809C (en) 2015-05-26
US7696185B2 (en) 2010-04-13

Similar Documents

Publication Publication Date Title
CN101443340B (zh) 前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法
Lattuada et al. The synthesis and application of polyamino polycarboxylic bifunctional chelating agents
JP2010174013A (ja) 組織ダメージの治療と予防
JP5271912B2 (ja) 標的化リガンドを固定化するための改良型リンカー
JP2005531559A5 (enExample)
JP2006523237A5 (enExample)
US11414455B2 (en) Toll-like receptor 2 ligands and methods of making and using thereof
CN105407920A (zh) 靶向癌症、尤其是前列腺癌的合成性抗体模拟化合物(SyAMs)
JP2005507857A (ja) 改変ｐｓｍａリガンド及びそれに関する利用
US20250367312A1 (en) Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer
JP2007521254A (ja) 診断画像用化合物
RU2697519C1 (ru) Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
US20240398962A1 (en) Dendrimer-glutamine antagonist conjugates and methods of use thereof
US7943775B2 (en) Small molecules for imaging protein-protein interactions
TWI689503B (zh) 以鋅結合劑為基礎的ｅｂｎａ１專一性化合物
CN101410139A (zh) 施陶丁格连接在生物活性化合物的体内组装中的用途
JP2011026283A (ja) 分子イメージングのための蛍光標識化合物およびその利用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140123

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140603